Browsing by Author "Arslan, M.E."

Now showing 1 - 2 of 2

Neuroprotective Effects of Geranium Robertianum L. Aqueous Extract on the Cellular Parkinson’s Disease Model
(Verduci Editore s.r.l, 2023) Arslan, M.E.; Yilmaz, A.
OBJECTIVE: In recent years, botanical medicines alone or in conjunction with existing therapies have attracted considerable popularity as an alternative treatment for Parkinson’s Disease (PD). For instance, Geranium robertianum L. (Geraniaceae family) has been used in folk medicine for its antioxidant and anti-inflammatory properties. However, its neuroprotective potential has not been well demonstrated. MATERIALS AND METHODS: Herein and for the first time, we have investigated the in vitro neuroprotective effects of leaf extract of G. Robertianum over a wide dose range (0-200 µg/mL) on the PD model using retinoic acid (RA)-differentiated SHSY-5Y cells and 1-methyl-4-phenylpyridinium (MPP+)-induced neurotoxicity. The neuroprotective effects were determined by 3-(4,5-dimethylth-iazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and lactate dehydrogenase (LDH) release assays. The antioxidant activity of the extract was measured by total antioxidant status (TAS) and total oxidant status (TOS). The effect of leaf aqueous extracts on acetylcholinesterase (AChE) activity was also determined. Finally, cell death mechanisms were analyzed by flow cytometry. RESULTS: Our results showed that G. Robertianum leaf extract ameliorated cytotoxicity and oxidative damage by MPP+. Moreover, G. Robertianum extract exhibited a protective activity against MPP+ induced apoptosis. CONCLUSIONS: The current findings could lead to a promising new candidate for a possible cure of Parkinson’s disease through neuroprotective mechanisms with respect to antioxidant and apoptosis inhibitory properties of G. Robertianum water extracts. © 2023 Verduci Editore s.r.l. All rights reserved.
Pivotal Role of Micronucleus Test in Drug Discovery
(Nova Science Publishers, Inc., 2019) Türkez, H.; Arslan, M.E.; Mardinoğlu, A.
Early detection of adverse effects of novel compunds during drug discovery and development most probably reduce late stage failures, expenses and exertions for candidate drugs. Although the micronucleus (MN) test is one of the oldest techniques used in biochemical sciences for drug discovery. Flexibility of the technique for both in vitro and in vivo applications and practicability for large scale samples in short time make the MN test an inevitable tool for chemical trails. Drug studies require a formulation that provides the highest exposure to detect clastogenic and aneugenic activities and thus analysis makes it possible to get the necessary safety margin to support clinical trials. The MN test is one of the most important tools of the genotoxicity test battery in preclinical studies to identify negative effects of compounds that induce numerical and structural chromosome alterations in wide spectrum concentrations. The MN assay can be applied various cell types in different protocols. For instance; the most recommended protocols are bone the marrow micronucleus analysis and the in vivo mammalian erythrocyte precursor assay. Also, the rodent ovary cells validation test is a very powerful approach to analyse side effects of a compound. Beside cell types, detection systems can be constituted to obtain a high throughput screening such as integrating flow cytometry analysis into the MN inspections. Since a new compound is needed for such an assay, the MN test can assess abnormalities earlier in the drug discovery pipeline, making structure/genotoxicity connection a possible system for drug characterization. © 2020 by Nova Science Publishers, Inc. All rights reserved.